Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.50 |
| ▸ | CA1 | P00915 | 15/20 | 0.50 |
| ▸ | CA12 | O43570 | 14/20 | 0.50 |
| ▸ | CA9 | Q16790 | 13/20 | 0.50 |
| ▸ | CA7 | P43166 | 5/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246187 | 0.82 | CA1 (0.47) | CA2CA1CA12CA9CA7 | |
| SCHEMBL6168325 | 0.82 | MAPT (0.50) | PSMB1PSMB5 | |
| SCHEMBL31241117 | 0.82 | MAPT (0.55) | PSMB1PSMB5 | |
| SCHEMBL13392342 | 0.81 | PSMB1 (0.48) | PSMB1PSMB5 | |
| SCHEMBL31241086 | 0.81 | PSMB1 (0.48) | PSMB1PSMB5 | |
| SCHEMBL6181448 | 0.79 | DDR1 (0.44) | PSMB1PSMB5MMP13 | |
| SCHEMBL2419436 | 0.78 | MAPK8 (0.45) | CA2CA1CA12CA9PSMB1 | |
| SCHEMBL6168739 | 0.77 | FGFR1 (0.48) | PSMB1PSMB5 | |
| SCHEMBL5697120 | 0.77 | MMP13 (0.69) | CA2CA1CA12CA9CA7 | |
| SCHEMBL6171027 | 0.76 | EGLN1 (0.53) | PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | CA2 503/4885CA1 1576/4885CA12 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.